NCT04098237进行中（未招募）2 期
Pancreatic-enzyme Replacement Therapy With Pancreaze (Pancrelipase) Delayed-release in Addition to Standard of Care for Borderline Resectable, Locally Advanced, and Advanced Pancreatic Adenocarcinoma Patients (PANCAX-3) With Cachexia and Exocrine Pancreatic Insufficiency
Andrew Hendifar, MD1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2020年12月17日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Feasibility of Completing Pancreatic Enzyme Replacement Therapy During the First 8 Weeks of the Study: Daily Compliance Diary
研究概览
简要总结
The objective of this study is to assess weight stability, functional changes, and quality of life when Pancreaze (pancrelipase) delayed-release 84,000-lipase units (capsules), for main meals, and 42,000-lipase units (capsules), for snacks, are added to standard of care in patients with exocrine pancreatic insufficiency due to pancreatic adenocarcinoma. This will be the first prospective study of this particular formulation in addition to standard of care in advanced pancreatic cancer patients. We will treat 40 consecutive patients with borderline resectable, locally advanced and advanced pancreatic cancer patients who present with weight loss and exocrine pancreatic insufficiency with this advanced formulation of Pancreaze.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Borderline resectable, locally advanced, and advanced pancreatic cancer patients (can include new or recurrent diagnosis) referred to SOCCI-CSMC (Samuel Oschin Cancer Center - Cedars Sinai Medical Center)
- •Age ≥ 18 years.
- •ECOG performance status 0-1 or Karnofsky PS >60%
- •Clinical diagnosis of exocrine pancreatic insufficiency
- •Cachexia defined as at least 5% weight loss in the presence of chronic illness, within any 6-month period prior to screening OR as documented by the medical physician based on standard diagnosis of cachexia
- •Life expectancy of greater than 3 months, in the opinion of the investigator.
- •Patients must have normal organ and marrow function as defined below:
- •Absolute Neutrophil Count (ANC) ≥ 500/mcL
- •Platelets ≥ 50,000/mcL
- •Total bilirubin ≤ 5X upper limit of normal (ULN)
- •AST(SGOT)/ALT(SGPT) ≤ 5 X ULN
- •Creatinine OR creatinine clearance ≤ 3 times the upper limit of normal OR ≥ 30 mL/min/1.73 m² for patients with creatinine levels above normal.
- •Note: Patients with biliary stents are eligible provided that all other inclusion criteria are met.
- •Woman of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from the time of signing the informed consent form, for the duration of study participation, and for at least 30 days after discontinuing from study treatment.
- •Ability to understand and the willingness to sign a written informed consent document
排除标准
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Women who are pregnant or are breastfeeding
- •Dementia or altered mental status that would prohibit the understanding or rendering of informed consent
- •Unable to swallow intact capsules
- •Fibrosing colonopathy: Patients with history of fibrosing colonopathy have been reported to experience advancement to colonic strictures with doses of lipase>6000 units/kg/meal over prolonged periods of time.
- •History of chronic illness associated with malabsorption or nutrient deficiency including but not limited to chronic pancreatitis, cystic fibrosis, celiac disease, Crohn's disease, pernicious anemia and/or prior intestinal resection.
- •Coexistent other primary malignancy
- •Pregnancy, breastfeeding, or of childbearing potential and not willing to use methods of birth control during the study
- •Active drug abuse or intoxication with any substance including alcohol (blood alcohol content >0.08%, legal driving limit)
- •Known allergy to any of the active ingredients in pancreatic enzyme supplementation
- •Concurrent use of pancreatic enzyme supplementation or over the counter supplements which contain lipase, protease, and amylase as active ingredients
研究组 & 干预措施
Standard of care treatment with Pancreaze (pancrelipase)
Experimental
Pancrelipase capsules; 84,000 IU lipase units per main meal and 42,000 IU lipase units per snack; for 24 weeks
干预措施: Pancrelipase (Drug)
结局指标
主要结局
Feasibility of Completing Pancreatic Enzyme Replacement Therapy During the First 8 Weeks of the Study: Daily Compliance Diary
时间窗: 8 weeks
Adherence to therapy of at least 50% of the needed total lipase units, recorded using a daily compliance diary.
次要结局
- Mean Change in Weight From Baseline Through the End-of-study Visit(6 months)
- Mean Change in Calories Consumed From Baseline Through the End-of-study Visit(6 months)
- Mean Change in Stool Frequency From Baseline Through Cycle 3 Day 1(8 weeks)
- Mean Change in Stool Consistency From Baseline Through Cycle 3 Day 1(8 weeks)
- Mean Change in Serum Levels of Fat-soluble Vitamins From Baseline - Vitamin A(6 months)
- Mean Change in Serum Levels of Fat-soluble Vitamins From Baseline - Vitamin D(6 months)
- Mean Change in Serum Levels of Fat-soluble Vitamins From Baseline - Vitamin E(6 months)
- Mean Change in Serum Levels of Fat-soluble Vitamins From Baseline - Vitamin K(6 months)
- Mean Change in Serum Levels of Fat-soluble Vitamins From Baseline - Vitamin K PT(6 months)
- Change in Microbiome From Baseline(8 weeks)
- Mean Change in Daily Activity (Steps Taken) From Baseline(6 months)
- Mean Change in Daily Activity (Stairs Climbed) From Baseline(6 months)
- Mean Change in Sleep Disturbance From Baseline(6 months)
- Mean Change in Duration of Sleep Disturbances From Baseline(6 months)
- Mean Change in Average Heart Rate From Baseline(6 months)
- Mean Change in Peak Heart Rate From Baseline(6 months)
- Mean Change in Daily Active Minutes From Baseline(6 months)
研究者
Andrew Hendifar, MD
Sponsor-Investigator
Cedars-Sinai Medical Center
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
The effect of pancreatic enzyme replacement therapy on glucose metabolism and nutritional parameters in patients with diabetes mellitusEUCTR2015-005491-20-HUActavis Hungary Gyógyszermarketing és Kereskedelmi Korlátolt Felelosségu Társaság
招募中
3 期
Status and effect of pancreatic enzymes on intestinal health and energy spent at rest in patients with chronic pancreatitis as compared to healthy controlsCTRI/2020/12/029888ICMR
终止
1 期
PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic CancerPancreatic InsufficiencyPancreatic Enzyme AbnormalityPancreatic CancerNCT02985801Massimo Raimondo, M.D.16
已完成
不适用
The Role of oAncreatic Enzyme ReplAcement Therapy (PERT) on Mucosal Visibility Before Upper GI EndoscopyUpper Gastrointestinal EndoscopyNCT06218537Carol Davila University of Medicine and Pharmacy42
尚未招募
不适用
Effect of digestive enzymes supplement on bacterial diversity in patients with chronic pancreatitisCTRI/2020/10/028302Indian Council of Medical Research